Coverage of BOLT remains limited, and every published target was issued before the October 2026 merger. The two most recent figures are a $7.00 Buy rating from H.C. Wainwright’s Robert Burns (reiterated March 13, 2026) and a $22.00 Buy rating from Rodman & Renshaw’s Michael King Jr. (May 28, 2026). Their midpoint of $14.50 serves as the reference point here. Earlier calls, such as Lake Street’s $75 Buy (adjusted post reverse split) and Leerink Partners’ $6 Hold, illustrate the broad dispersion among the few analysts who follow the name. No updates have appeared since the Prana transaction, so these figures reflect the prior pipeline rather than the restructured entity.
BOLT closed at $6.08 on November 13, 2026, inside a 52-week range of $3.10 to $7.78. Achieving the $14.50 level from that price would demand roughly 138% appreciation. The October 2026 deal, which brought in Prana Therapies and raised $120 million gross via a Series D PIPE plus warrants (with potential for another $60 million upon exercise), left legacy shareholders with about 6.9% of the fully diluted equity. Prana holders hold roughly 51.7% and new investors about 41.4%, effectively transferring control.
The reoriented pipeline and improved capital position provide the primary support. Lead candidate PRA-216, an IL-4Rα/TSLP bispecific antibody, is advancing in Phase 2 trials for asthma, COPD, and atopic dermatitis, with a fourth study in eosinophilic esophagitis planned; proof-of-concept data is anticipated in 2027. The acquired INSPIRE platform offers a next-generation multispecific antibody approach. The $120 million financing extends the runway and is intended to cover multiple milestones. I also checked comparable names using Tickeron’s AI Screener to gauge industry context.
Structural and clinical hurdles remain substantial. The company posted a roughly $19.6 million net loss in the third quarter of 2026 with minimal revenue and continues to operate at a loss against a common-share market value well under $20 million. Conversion of Series D preferred stock, a possible reverse split (ratios from 1-for-2 to 1-for-12) for Nasdaq compliance, and potential increases in authorized shares all signal further dilution. Any setback with PRA-216 or delays in the 2027 readouts would undermine the core thesis, while an announced shareholder investigation into merger terms adds governance questions.
The 52-week high of $7.78, reached in late October 2026, sits just above current levels and marks the nearest resistance. A sustained break above that area would represent the first concrete step toward $14.50. The September 2026 low of $3.10 serves as the key support zone. With a small float and modest trading volume, price swings can be pronounced in either direction.
Analyst targets generally look out about 12 months, though none postdate the merger. Near-term focus should remain on the 2027 Phase 2 readouts for PRA-216, any further financing or votes on preferred conversion and a possible reverse split, and potential new analyst coverage. Quarterly cash-burn updates and Nasdaq compliance developments also merit attention. From what I see, monitoring these catalysts closely will be essential.
I frequently review Tickeron’s AI Daily Buy/Sell Signals when evaluating lower-float, event-driven names. The tool applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals drawn from technical patterns and market shifts. It offers a practical way to supplement manual analysis and track evolving trends without replacing individual judgment.
The $14.50 central target averages the two latest analyst calls and implies a substantial 138% advance from the recent $6.08 close. The constructive case rests on PRA-216’s multi-indication Phase 2 program, the INSPIRE platform, and the $120 million financing. The opposing view highlights dilution from the reverse merger, ongoing losses, a sub-$20 million market value, and binary clinical risk. Because every published target predates the merger and the analyst range is unusually wide, the $14.50 figure functions best as a directional reference rather than a firm prediction. Ultimately, the 2027 clinical data will carry far more weight than any prior target.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.
BOLT saw its Momentum Indicator move below the 0 level on November 09, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 105 similar instances where the indicator turned negative. In 98 of the 105 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The 10-day RSI Indicator for BOLT moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 12 similar instances where the indicator moved out of overbought territory. In 10 of the 12 cases, the stock moved lower in the following days. This puts the odds of a move lower at 83%.
The Moving Average Convergence Divergence Histogram (MACD) for BOLT turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 41 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BOLT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
BOLT moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for BOLT crossed bullishly above the 50-day moving average on October 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.
The 50-day moving average for BOLT moved above the 200-day moving average on November 11, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +61.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where BOLT advanced for three days, in 156 of 202 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
BOLT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 78 of 92 cases where BOLT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. BOLT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.997) is normal, around the industry mean (3.498). P/E Ratio (-0.396) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (1.355) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 88 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BOLT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology